title: Ex vivo expansion of umbilical cord blood hematopoietic progenitor cells by combinations of cytokines.
abstract: Ex vivo expansion of hematopoietic progenitor cells in the umbilical cord blood mononuclear cells (CB-MNC) was investigated in liquid culture system with various combinations of cytokines (stem cell factor [SCF], interleukin [IL]-3, IL-6, granulocyte-colony stimulating factor [G-CSF], erythropoietin [EPO], and interferon [INF]-gamma). Non-lineage-committed hematopoietic progenitor cells and lineage committed hematopoietic progenitor cells were represented as CD34+CD38- and CD34+CD38+ subpopulations, respectively. Although absolute CD34+CD38- cell numbers decreased even in the presence of multicytokines, the combinations of SCF plus IL-6 and SCF plus IL-3 plus IL-6 plus IFN-gamma were significantly effective in maintaining CD34+CD38- cells than the other combinations (P < 0.05). After 4 weeks of culture. CD34+CD38- cells disappeared in all combinations of cytokines. Absolute CD34+CD38+ cell numbers increased in the presence of cytokines. Maximal expansion of CD34+CD38+ cells were observed in the combinations of SCF plus IL-3 plus IL-6 plus EPO (19.8 +/- 3.3-fold) and SCF plus IL-3 plus IL-6 plus G-CSF (18.3 +/- 2.6). The combination of SCF plus IL-3 plus IL-6 was also effective to expand CD34+CD38- cells (15.8 +/- 3.9). However, the expansion was transient and they decreased to zero within 3 weeks. In the combinations of SCF plus IL-6 and SCF plus IL-3 plus IL-6 plus INF-gamma, maximal expansion was inferior to the others but CD34+CD38+ cells were maintained more than 4 weeks. These results suggested that the indication of CBT can be expanded into older children by ex vivo augmentation of CB hematopoietic progenitor cells using multi-cytokines.
authors.affiliation: Department of Pediatrics, Jikei University of School of Medicine, Minato-ku, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Urashima
authors.forename: Y
authors.initials: Y
authors.lastname: Hoshi
authors.forename: M
authors.initials: M
authors.lastname: Akiyama
authors.forename: M
authors.initials: M
authors.lastname: Kamijo
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: J
authors.initials: J
authors.lastname: Akatsuka
authors.forename: K
authors.initials: K
authors.lastname: Maekawa
authors.forename: M
authors.initials: M
authors.lastname: Matsuzaki
authors.forename: J
authors.initials: J
authors.lastname: Ohnishi
authors.forename: C
authors.initials: C
authors.lastname: Kaihara
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D016207:Cytokines / Q000494:pharmacology*; D005312:Fetal Blood / Q000166:cytology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007231:Infant, Newborn; D008562:Membrane Glycoproteins; D009699:N-Glycosyl Hydrolases; D010641:Phenotype
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D016207:Cytokines; D008562:Membrane Glycoproteins; D009699:N-Glycosyl Hydrolases; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1